dragon

Azerbaijan Medical Journal

Scopus Indexed (2026)

Scopus Indexed Journal & Country Rank

SJR (2026)

Scimago Journal & Country Rank
Aim and Scope

Azerbaijan Medical Journal

The Azerbaijan Medical Journal (AMJ) is a peer-reviewed, open-access monthly publication dedicated to advancing medical science and clinical practice through the dissemination of high-quality, original research. The Journal aims to serve as a global platform for researchers, clinicians, and healthcare professionals to share innovative findings, critical reviews, and evidence-based insights that contribute to the understanding, prevention, diagnosis, and treatment of diseases.

AMJ welcomes submissions across a broad spectrum of medical disciplines, including but not limited to:

  • • Internal Medicine and its subspecialties
  • • Surgery and surgical innovations
  • • Pediatrics and neonatology
  • • Obstetrics, gynecology, and reproductive health
  • • Public health, epidemiology, and global health
  • • Medical education and health policy
  • • Pharmacology and therapeutics
  • • Diagnostic imaging and laboratory medicine
  • • Emerging infectious diseases and pandemic preparedness
  • • Translational and interdisciplinary medical research
  • • Dental health

The Journal particularly encourages contributions from early-career researchers, multidisciplinary teams, and authors from underrepresented regions. All manuscripts undergo rigorous double-blind peer review to ensure scientific integrity, methodological soundness, and relevance to contemporary medical challenges.We invite authors worldwide to submit original articles, review papers, case reports, brief communications, and study protocols that align with the Journal’s mission of promoting excellence, equity, and accessibility in medical scholarship.

📝 Official Submission Process

Manuscripts must be submitted officially through our online system. Please complete the REGISTRATION FORM on our website first to access your Author Dashboard. You may then submit your manuscript for an initial review by our dedicated editorial team to assess its compliance with our journal's policies and scope.

Step-by-Step Submission Process:
  1. 1. Complete registration Form
  2. 2. Access Your Applicant Dashboard
  3. 3. Submit a new article
  4. 4. Fill Out the Submission Form.
    Please ensure you provide a title and abstract for your article, and upload the required document files.
    Accepted formats are PDF, TXT, and DOCX (up to 10MB per file). You may upload up to 5 files.
    The first document file is mandatory.
💡 Need Help?

For technical assistance with submission or registration, please contact:

For general editorial questions or policy inquiries:

Latest Articles

Azerbaijan Medical Journal

AMJ-17-04-2026-12376
AI-Integrated Multi-Omic Liquid Biopsy for Rapid Diagnosis of EBV-Associated Burkitt Lymphoma in the Greater Mekong Region: A Prospective Diagnostic Accuracy Study

Author(s): Ana María Hernández Vázquez, J.C. Jaime-Fagundo Fagundo

Abstract: Background: Burkitt lymphoma (BL) is a highly aggressive childhood cancer endemic to Epstein-Barr virus (EBV) and malaria regions. Diagnostic delays exceeding 90 days are common in resource-limited settings due to scarce pathology infrastructure. We developed and validated an artificial intelligence (AI)-integrated, multi-omic liquid biopsy platform for rapid BL diagnosis in the Greater Mekong Subregion. Methods: We conducted a prospective, multicenter diagnostic accuracy study across eight hos...
Read More Azerbaijan Medical Journal • 17-04-2026
AMJ-17-04-2026-12375
Deep Learning-Integrated Multi-Omic Liquid Biopsy for Rapid Diagnosis of EBV-Associated Burkitt Lymphoma in the Eastern Mediterranean: A Prospective Diagnostic Accuracy Study

Author(s): Nikolaos Papadopoulos, Maria Eleftheriadou

Abstract: Background: Burkitt lymphoma (BL) is a highly aggressive non-Hodgkin lymphoma endemic to Epstein-Barr virus (EBV) and malaria regions. Diagnostic delays exceeding 90 days remain prevalent in resource-limited settings due to scarce pathology infrastructure. We developed and validated an artificial intelligence (AI)-integrated, multi-omic liquid biopsy platform for rapid BL diagnosis across the Eastern Mediterranean region. Methods: We conducted a prospective, multicenter diagnostic accuracy stud...
Read More Azerbaijan Medical Journal • 17-04-2026
AMJ-17-04-2026-12374
Perceptions of the professional liability insurance system among health care workers: a cross-sectional study

Author(s): Nazykesh Akhmetoldinova, Zhanna Tlembayeva, Rauan Zhaltyrbayeva, Zhorabek Abraliyev, Malike Kudaibergenova

Abstract: Objectives: This study aimed to assess healthcare workers’ perceptions of the current professional liability insurance system in the Republic of Kazakhstan. It was hypothesized that, despite a neutral overall evaluation, healthcare workers would report limited practical protection and identify insufficient transparency and institutional awareness as key challenges. Differences in perceptions by sector, length of service, and professional category were examined, along with predictors of support f...
Read More Azerbaijan Medical Journal • 17-04-2026
AMJ-17-04-2026-12373
Intravitreal Photoswitch Therapy with KIO-302 in Advanced Retinitis Pigmentosa: A Phase 1/2 Randomized, Controlled Trial

Author(s): Robert J. Casson, Rajesh Kumar Verma

Abstract: Background: Retinitis pigmentosa (RP) comprises a heterogeneous group of inherited retinal degenerations with no approved pharmacological therapies for late-stage disease. KIO-302 is a next-generation azobenzene photoswitch designed to restore light sensitivity to surviving retinal ganglion cells (RGCs) in advanced photoreceptor degeneration. We report the first randomized, controlled evaluation of intravitreal KIO-302 in patients with advanced RP. Methods: In this Phase 1/2, randomized, single...
Read More Azerbaijan Medical Journal • 17-04-2026
AMJ-29-03-2026-12372
Osimertinib with platinum–pemetrexed versus oismertinib monotherapy in EGFR-mutated non-small-cell lung cancer with concurrent tumor suppressor gene alterations: A randomized, double-blind, placebo-controlled phase 3 trial (BRAZIL-TSG)

Author(s): Carlos A. Silva, MD, PhD, Maria G. Santos, MD

Abstract: Background: Third-generation epidermal growth factor receptor–tyrosine kinase inhibitors (EGFR-TKIs) are standard first-line therapy for EGFR-mutated non-small-cell lung cancer (NSCLC). However, co-existing tumor suppressor gene (TSG) alterations (e.g., TP53, RB1) are associated with inferior outcomes. The ACROSS2 trial demonstrated improved progression-free survival (PFS) with aumolertinib plus chemotherapy versus monotherapy in this population, but was limited by an open-label design a...
Read More Azerbaijan Medical Journal • 29-03-2026
dragon